The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemia.
作者信息
Verhoeft Krista, Cools Jan
机构信息
Center for Human Genetics, KU Leuven
VIB Center for Cancer Biology, Leuven, Belgium
出版信息
Haematologica. 2024 Nov 1;109(11):3461-3462. doi: 10.3324/haematol.2023.284524.
Abstract
摘要
相似文献
1
The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemia.
Haematologica. 2024 Nov 1;109(11):3461-3462. doi: 10.3324/haematol.2023.284524.
2
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Clin Cancer Res. 2023 Nov 14;29(22):4613-4626. doi: 10.1158/1078-0432.CCR-22-2562.
3
A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Cancer Genet. 2017 Oct;216-217:91-99. doi: 10.1016/j.cancergen.2017.07.007. Epub 2017 Aug 3.
4
Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective multicenter study.
Cancer. 2024 Nov 15;130(22):3902-3912. doi: 10.1002/cncr.35481. Epub 2024 Aug 13.
5
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes.
Diagn Pathol. 2012 Feb 22;7:19. doi: 10.1186/1746-1596-7-19.
6
A Case of a Very Young Child With T Lymphoblastic Lymphoma With Eosinophilia and PDGFRB Translocation: A Rare Form of Myeloid/Lymphoid Neoplasm Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB or FGFR1.
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e990-e993. doi: 10.1016/j.clml.2020.08.016. Epub 2020 Aug 22.
7
Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Am J Clin Pathol. 2021 Feb 4;155(2):160-178. doi: 10.1093/ajcp/aqaa208.
8
Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
Haematologica. 2024 May 1;109(5):1373-1384. doi: 10.3324/haematol.2023.283981.
9
Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Acta Haematol. 2019;141(2):119-127. doi: 10.1159/000495687. Epub 2019 Feb 6.
10
Pdgfra and Pdgfrb genetically interact during craniofacial development.
Dev Dyn. 2016 Jun;245(6):641-52. doi: 10.1002/dvdy.24403. Epub 2016 Apr 5.
本文引用的文献
1
Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
Haematologica. 2024 May 1;109(5):1373-1384. doi: 10.3324/haematol.2023.283981.
2
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Clin Cancer Res. 2023 Nov 14;29(22):4613-4626. doi: 10.1158/1078-0432.CCR-22-2562.
3
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.
Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. eCollection 2021 Nov.
4
Potential targeting of FLT3 acute myeloid leukemia.
Haematologica. 2021 Mar 1;106(3):671-681. doi: 10.3324/haematol.2019.240754.
5
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.
6
Targeting the PDGF signaling pathway in tumor treatment.
Cell Commun Signal. 2013 Dec 20;11:97. doi: 10.1186/1478-811X-11-97.
7
History of discovery: platelet-derived growth factor.
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2397-401. doi: 10.1161/ATVBAHA.108.179556.
8
PHF6 mutations in T-cell acute lymphoblastic leukemia.
Nat Genet. 2010 Apr;42(4):338-42. doi: 10.1038/ng.542. Epub 2010 Mar 14.
9
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia. 2007 Jun;21(6):1183-8. doi: 10.1038/sj.leu.2404662. Epub 2007 Mar 22.
10
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Gastroenterology. 2005 Feb;128(2):270-9. doi: 10.1053/j.gastro.2004.11.020.
Zotero 插件